Amazon Web Services (AWS) is teaming up with EvolutionaryScale, a biology-focused artificial intelligence company, to offer scientists and researchers access to the startup’s ESM3 language models via AWS. This collaboration aims to advance drug discovery by facilitating the development of new proteins. EvolutionaryScale recently secured $142 million in seed funding, with support from Nat Friedman, Daniel Gross, Lux Capital, AWS, and Nvidia’s venture capital arm. The company’s ESM3 AI model, designed to create new complex proteins, incorporates antibody knowledge and protein design workflows. Trained on diverse biological data, ESM3 can generate proteins that have never existed before, potentially streamlining the process of bringing new therapies to market.
ESM3 consists of three proprietary models and one open-source model, which AWS customers can access through Amazon SageMaker and AWS HealthOmics. The open-source version will also be available on Amazon Bedrock in the near future. This initiative aligns with the industry trend towards leveraging AI models for drug discovery and therapeutic development. For instance, Google recently introduced Tx-LLM, a therapeutic-focused language model derived from PaLM-2, the company’s generative AI technology. Tx-LLM uses free-text instructions and small molecule representations, such as SMILES strings, to address tasks related to drug discovery and therapy development. SMILES, a molecular entry system, employs printable characters to depict molecules and reactions. The development of TxT, a collection of therapeutic instructions, enables Tx-LLM to tackle classification, regression, and generation tasks in the drug discovery realm.
Furthermore, the HIMSS AI in Healthcare Forum, scheduled for September 5-6 in Boston, will feature discussions on the latest advancements in AI applications within the healthcare sector. Attendees can gain insights into how AI technologies are revolutionizing drug discovery, therapy development, and other aspects of healthcare delivery. This event provides a platform for industry experts to share their experiences and explore the potential of AI-driven innovations in healthcare. By bringing together key stakeholders, the forum aims to foster collaboration and accelerate the adoption of AI solutions for improving patient care and outcomes.
Article Source
https://www.mobihealthnews.com/news/aws-partners-evolutionaryscale-following-its-142m-raise
